Targeted therapy use following Medicare’s coverage expansion for next-generation sequencing in older adults with lung cancer

Clicks: 2
ID: 333394
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #73 of 74 articles by views in jnci cancer spectrum

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract PURPOSE To examine whether Medicare’s 2018 National Coverage Determination (NCD) for next-generation sequencing (NGS) was associated with changes in the use of targeted oral anticancer therapies among older adults with lung cancer. METHODS Retrospective cohort study. Multivariable logistic regression was used to estimate the probability of initiating an oral targeted therapy within 12 months of diagnosis. Key exposures were (1) diagnosis before versus after the NCD and (2) residence in a region with versus without pre-NCD NGS. Data were drawn from the SEER–Medicare linked data with Part D claims, including diagnosis years 2016–2019 with follow-up through 2020. The analytic sample included Medicare fee-for-service Part D beneficiaries aged 65 years or older with newly diagnosed lung cancer. RESULTS Among 30,855 Medicare fee-for-service Part D beneficiaries with lung cancer, 7.1% used targeted oral anticancer therapies. The NCD was not associated with a significant overall change in targeted therapy use (0.4 Percentage Point; 95% CI, −1.6 to 2.4; p = 0.71). Before NCD implementation, targeted therapy use was 1.0 PP higher in regions with pre-NCD NGS coverage than in regions without such coverage (95% CI, 0.2–1.9; p = 0.015). In stage-stratified analyses, the additional post-NCD change was significant among patients with distant-stage disease (3.2 PPs; 95% CI, 2.6–4.0; p < 0.001) but not among those with regional-stage disease (p = 0.29). CONCLUSIONS Medicare's NCD for NGS was not associated with a significant overall increase in targeted oral anticancer therapy use but was associated with increased use among patients with distant-stage disease. Targeted therapy use remained higher in regions with preexisting NGS coverage.
Reference Key
openalex_W7223114152 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors So-Yeon Kang, Patrick C. Roney, Jaeil Ahn, Tania Lobo, Carole Roan Gresenz, Arnold L. Potosky, Anita Yeomans Kinney, Marc D. Schwartz
Journal jnci cancer spectrum
Year 2026
DOI
10.1093/jncics/pkag113
URL
https://doi.org/10.1093/jncics/pkag113
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.